Jamie M O'sullivan

List of Publications by Year
in descending order

43 papers	1,992 citations	236925 25 h-index	276875 41 g-index
43 all docs	43 docs citations	43 times ranked	3227 citing authors

#	Article	IF	Citations
1	COVID19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1044-1049.	2.5	307
2	Persistent endotheliopathy in the pathogenesis of long COVID syndrome. Journal of Thrombosis and Haemostasis, 2021, 19, 2546-2553.	3.8	208
3	Prolonged elevation of Dâ€dimer levels in convalescent COVIDâ€19 patients is independent of the acute phase response. Journal of Thrombosis and Haemostasis, 2021, 19, 1064-1070.	3.8	142
4	Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematology,the, 2020, 7, e553-e555.	4.6	122
5	Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood, 2017, 130, 2344-2353.	1.4	98
6	Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVIDâ€19): evidence of acute and sustained endothelial cell activation. British Journal of Haematology, 2021, 192, 714-719.	2.5	92
7	Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Advances, 2018, 2, 1784-1791.	5.2	79
8	The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. Blood, 2020, 136, 2864-2874.	1.4	75
9	More on COVIDâ€19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1060-1061.	2.5	73
10	Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. Blood, 2013, 122, 4107-4110.	1.4	65
11	ADAMTS13 regulation of VWF multimer distribution in severe COVIDâ€19. Journal of Thrombosis and Haemostasis, 2021, 19, 1914-1921.	3.8	58
12	Emerging roles for hemostatic dysfunction in malaria pathogenesis. Blood, 2016, 127, 2281-2288.	1.4	54
13	A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance. Blood, 2018, 131, 911-916.	1.4	54
14	Von Willebrand factor and cancer; metastasis and coagulopathies. Journal of Thrombosis and Haemostasis, 2020, 18, 2444-2456.	3.8	54
15	von Willebrand factor clearance â€“ biological mechanisms and clinical significance. British Journal of Haematology, 2018, 183, 185-195.	2.5	51
16	Advances in understanding the molecular mechanisms that maintain normal haemostasis. British Journal of Haematology, 2019, 186, 24-36.	2.5	46
17	A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria. Blood, 2016, 127, 1192-1201.	1.4	41
18	Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function. Blood, 2019, 133, 1371-1377.	1.4	36

#	Article	IF	Citations
19	More on â€˜Association between ABO blood groups and risk of SARSâ€CoVâ€2 pneumoniaâ€™. British Journal of Haematology, 2020, 190, 27-28.	2.5	35
20	Emerging Roles for von Willebrand Factor in Cancer Cell Biology. Seminars in Thrombosis and Hemostasis, 2018, 44, 159-166.	2.7	34
21	Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood, 2019, 133, 1585-1596.	1.4	32
22	N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance. Blood, 2016, 128, 1959-1968.	1.4	31
23	Advances in understanding the molecular mechanisms of venous thrombosis. British Journal of Haematology, 2019, 186, 13-23.	2.5	31
24	von Willebrand factor sialylationâ€”A critical regulator of biological function. Journal of Thrombosis and Haemostasis, 2019, 17, 1018-1029.	3.8	30
25	Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1â€“A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 845-855.	2.4	29
26	The role of von Willebrand factor in breast cancer metastasis. Translational Oncology, 2021, 14, 101033.	3.7	18
27	Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration. Journal of Thrombosis and Haemostasis, 2022, 20, 2350-2365.	3.8	18
28	Advances in the Management of Cancer-Associated Thrombosis. Seminars in Thrombosis and Hemostasis, 2021, 47, 139-149.	2.7	16
29	The Biological Significance of von Willebrand Factor O-Linked Glycosylation. Seminars in Thrombosis and Hemostasis, 2021, 47, 855-861.	2.7	10
30	The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies. Journal of Thrombosis and Haemostasis, 2022, 20, 1766-1777.	3.8	10
31	Investigating the clearance of VWF Aâ€domains using siteâ€directed PEGylation and novel Nâ€linked glycosylation. Journal of Thrombosis and Haemostasis, 2020, 18, 1278-1290.	3.8	8
32	Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance. Haematologica, 2022, 107, 668-679.	3.5	8
33	Management of elective procedures in low von Willebrand factor patients in the LoVIC study. Journal of Thrombosis and Haemostasis, 2021, 19, 701-710.	3.8	7
34	Persistent endotheliopathy in the pathogenesis of long COVID syndrome â€•Reply to comment from von Meijenfeldt et al.. Journal of Thrombosis and Haemostasis, 2022, 20, 270-271.	3.8	5
35	Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor. Scientific Reports, 2020, 10, 18366.	3.3	3
36	Antithrombin inhibition using nanobodies to correct bleeding in hemophilia. EMBO Molecular Medicine, 2020, 12, e12143.	6.9	3

#	Article	IF	Citations
37	Hemostatic and protein C pathway dysfunction in the pathogenesis of experimental cerebral malaria. Haematologica, 2022, 107, 1950-1954.	3.5	3
38	von Willebrand factor promotes wound healing. Blood, 2019, 133, 2553-2555.	1.4	2
39	Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12532.	2.3	2
40	Personalized Approaches to the Treatment of Hemostatic Disorders. Seminars in Thrombosis and Hemostasis, 2021, 47, 117-119.	2.7	1
41	Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 214-228.	2.1	1
42	The Low Von Willebrand Factor in Ireland Cohort Study - Defining Optimal Management for Procedures in Patients with Low VWF (30-50 IU/dL). Blood, 2018, 132, 1178-1178.	1.4	0
43	Site-Directed Pegylation at Specific Sites Significantly Prolongs the Half-Life of A1A2A3-VWF By Markedly Attenuating LRP1-Mediated Clearance. Blood, 2018, 132, 1165-1165.	1.4	0